

Osseointegration von Implantaten bei der Einnahme unterschiedlicher Medikamente

Dr. Tim Wolff, Dr. Peter Schulz, Prof. Dr. Dr. Knut A. Grötz,

DENTALE IMPLANTOLOGIE, Ausgabe September

1. Branemark, P., G. Zarb, and T. Albrektsson, *Tissue-integrated prostheses: Osseointegration in clinical dentistry*. Quintessence Publishing Company, 1985. **54**(4): p. 611–612.
2. Koch, R. *Epidemiologisches Bulletin, aktuelle daten und informationen zu infektionskrankheiten und public health*. 2 2015; Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2015/Ausgaben/05_15.pdf;jsessionid=26F7BFA92A8B5DE3419FAF7F266086EB.2_cid363?__blob=publicationFile.
3. Groetz, K.A., E. Schiegnitz, and T.F. Wolff, *Handbuch MKG 2018: MKG-Update 2017 Kompromittierte Patienten*, Wiesbaden: Groetz, Knut A., Wiesbaden; Haßfeld, Stefan, Dortmund; Schmidt-Westhausen, Andrea M, Berlin; ISBN 978-3-86302-545-8. 2018.
4. Perez-Castrillon, J.L., et al., *Effect of the antihypertensive treatment on the bone mineral density and osteoporotic fracture*. *Curr Hypertens Rev* 2005(1): p. 61–66.
5. Pierroz, D.D., et al., *Deletion of beta-adrenergic receptor 1, 2, or both leads to different bone phenotypes and response to mechanical stimulation*. *J Bone Miner Res*, 2012. **27**(6): p. 1252-62.
6. Schlienger, R.G., et al., *Use of beta-blockers and risk of fractures*. *JAMA*, 2004. **292**(11): p. 1326-32.
7. Takeda, S., et al., *Leptin regulates bone formation via the sympathetic nervous system*. *Cell*, 2002. **111**(3): p. 305-17.
8. Brater, D.C., *Diuretic therapy*. *N Engl J Med*, 1998. **339**(6): p. 387-95.
9. Perez-Castrillon, J.L., et al., *Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms*. *Am J Hypertens*, 2003. **16**(6): p. 453-9.
10. Wu, X., et al., *Antihypertensive Medications and the Survival Rate of Osseointegrated Dental Implants: A Cohort Study*. *Clin Implant Dent Relat Res*, 2016. **18**(6): p. 1171-1182.
11. De Bruyne, P., et al., *Changes in prescription patterns of acid-suppressant medications by Belgian pediatricians: analysis of the national database, [1997-2009]*. *J Pediatr Gastroenterol Nutr*, 2014. **58**(2): p. 220-5.
12. Mazer-Amirshahi, M., et al., *Rising rates of proton pump inhibitor prescribing in US emergency departments*. *Am J Emerg Med*, 2014. **32**(6): p. 618-22.
13. Targownik, L.E., et al., *Use of proton pump inhibitors and risk of osteoporosis-related fractures*. *CMAJ*, 2008. **179**(4): p. 319-26.
14. O'Connell, M.B., et al., *Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial*. *Am J Med*, 2005. **118**(7): p. 778-81.
15. Ye, X., et al., *Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis*. *Eur J Gastroenterol Hepatol*, 2011. **23**(9): p. 794-800.
16. Grimelius, L., et al., *The parathyroid glands in experimentally induced hypergastrinemia in the rat*. *Scand J Gastroenterol*, 1977. **12**(6): p. 739-44.
17. Wu, X., et al., *Proton Pump Inhibitors and the Risk of Osseointegrated Dental Implant Failure: A Cohort Study*. *Clin Implant Dent Relat Res*, 2017. **19**(2): p. 222-232.
18. Chrcanovic, B.R., et al., *Intake of Proton Pump Inhibitors Is Associated with an Increased Risk of Dental Implant Failure*. *Int J Oral Maxillofac Implants*, 2017. **32**(5): p. 1097-1102.

19. Haney, E.M., et al., *Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men*. Arch Intern Med, 2007. **167**(12): p. 1246-51.
20. Chrcanovic, B.R., et al., *Is the intake of selective serotonin reuptake inhibitors associated with an increased risk of dental implant failure?* Int J Oral Maxillofac Surg, 2017.